Full data from the Phase III COMPASS Study with Xarelto (Rivaroxaban) have been featured in Hot Line presentations at ESC Congress 2017 on August 27, 2017 in Barcelona, Spain. On this occasion we will host a conference call for investors and analysts today, starting at ap-prox. 1:30 p.m. CEST (11:30 a.m. UTC).

Full data from the Phase III COMPASS Study with Xarelto (Rivaroxaban) will be featured in Hot Line presentations at ESC Congress 2017 on August 27, 2017 in Barcelona, Spain. On this occasion we will host a conference call for investors and analysts on August 28, starting at approx. 1:30 p.m. CEST (11:30 a.m. UTC).

Conforming to the proposal of the Board of Management and the Supervisory Board, the Annual Stockholders’ Meeting on April 28, 2017 passed the resolution to pay a dividend for fiscal 2016 of EUR 2.70 per share.

Reporting of the regions has been adjusted to reflect the distribution of responsibilities on the Board of Management.
Sales for Africa/Middle East are now no longer reported together with Latin America but with Europe.

Conforming to the proposal of the Board of Management and the Supervisory Board, the Annual Stockholders’ Meeting on April 29, 2016 passed the resolution to pay a dividend for fiscal 2015 of EUR 2.50 per share.

New: Information about the dividend for fiscal 2015
At its meeting on February 24, 2016, the Supervisory Board of Bayer AG approved the Board of Management\'s recommendation that a dividend payment of EUR 2.50 (2014: EUR 2.25) per share be proposed to the Annual Stockholders\' Meeting on April 29, 2016. With 826,947,808 shares entitled to the dividend, the total dividend payment would amount to EUR 2,067 million (2014: EUR 1,861 million), an increase of 11.1 percent.

With the company’s focus now on the Life Science businesses, a new organizational structure was introduced effective January 1, 2016. The company’s operations are now managed in three divisions – Pharmaceuticals, Consumer Health and Crop Science – and the Animal Health business unit.

This release provides restated figures for 2014 and Q1-Q3 2015 reflecting these changes in reporting structure. Restated figures for Q4 2015 will be available with the publication of FY 2015 results on February 25, 2016.

Conforming to the proposal of the Board of Management and the Supervisory Board, the Annual Stockholders’ Meeting on May 27, 2015 passed the resolution to pay a dividend for fiscal 2014 of EUR 2.25 per share.

At its meeting on February 25, 2015, the Supervisory Board of Bayer AG approved the Board of Management\'s recommendation that a dividend payment of EUR 2.25 (2013: EUR 2.10) per share be proposed to the Annual Stockholders\' Meeting on May 27, 2015. With 826,947,808 shares entitled to the dividend, the total dividend payment would amount to EUR 1,861 million (2013: EUR 1,737 million), an increase of 7.1 percent.

The Bayer Group is issuing a jumbo bond in 144A/Reg S format with a volume of USD 7 billion through its subsidiary Bayer U.S. Finance LLC, Pittsburgh, United States. The bond comprises six tranches with short-, mid- and long-term maturities.

Bayer intends in the future to focus entirely on the Life Science businesses – HealthCare and CropScience – and float MaterialScience on the stock market as a separate company. On this occasion we will host a conference call for investors and analysts today on September 18, 2014 from approx. 4:15 p.m. CEST (2:15 p.m. UTC).

Bayer has agreed to acquire the consumer care business of U.S. pharmaceutical company Merck & Co., Inc. and to engage in a strategic pharma cooperation in the field of soluble guanylate cyclase (sGC) modulators. On this occasion we will host a conference call for investors and analysts on May 6, 2014 from approx. 1:00 p.m. CEST.